Seattle Genetics, Inc. (NASDAQ:SGEN) Files An 8-K Results of Operations and Financial Condition

Item2.02

On April27, 2017, Seattle Genetics, Inc. issued a press release
announcing financial results for its first quarter ended March31,
2017. A copy of the press release is furnished herewith as
Exhibit99.1.

The information furnished with this report, including Exhibit
99.1, shall not be deemed filed for purposes of Section18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference into any other
filing under the Exchange Act or under the Securities Act of
1933, as amended, except as expressly set forth by specific
reference in such a filing.

(d) Exhibits.

About Seattle Genetics, Inc. (NASDAQ:SGEN)

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The Company’s pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. SGN-CD33A is an ADC composed of an anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia (AML). SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody indicated for the treatment of hematologic malignancies. SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal antibody indicated for the treatment of LIV-1-positive metastatic breast cancer.

Seattle Genetics, Inc. (NASDAQ:SGEN) Recent Trading Information

Seattle Genetics, Inc. (NASDAQ:SGEN) closed its last trading session up +1.33 at 68.26 with 638,542 shares trading hands.